Group 2: Dasatinib

DRUG2 trials

Sponsors

Mayo Clinic

Conditions

Chronic Kidney DiseaseStem Cell Transplant

Phase 1

Hematopoietic Stem Cell Transplant Survivors Study

CompletedNCT02652052

Mayo ClinicStem Cell Transplant

Start: 2016-03-01End: 2023-05-23Updated: 2025-01-15

Phase 2

Senescence in Chronic Kidney Disease

Enrolling by invitationNCT02848131

Mayo ClinicChronic Kidney Disease

Start: 2016-07-01End: 2027-04-01Target: 30Updated: 2026-05-19

Related Papers

Investigating the Molecular Mechanism of Quercetin Protecting against Podocyte Injury to Attenuate Diabetic Nephropathy through Network Pharmacology, MicroarrayData Analysis, and Molecular Docking

Evidence-based Complementary and Alternative Medicine2022-05-1616 citations

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.

2019-09-18951 citations